Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical application of all-trans-retinoic acid

A technology of all-trans retinoic acid and its use, which is applied in the field of pharmaceutical application of all-trans retinoic acid, and can solve problems such as unknown mechanism of action

Inactive Publication Date: 2016-07-13
SHANGHAI JIAO TONG UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In this strategy, the role of CXCL9 and CXCL10 is mainly to attract effector T cells to migrate to mucosal tissue, and whether they can differentiate into T RM It relies on the interaction between effector T cells and the local mucosal tissue microenvironment, the mechanism of which is still unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of all-trans-retinoic acid
  • Pharmaceutical application of all-trans-retinoic acid
  • Pharmaceutical application of all-trans-retinoic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] In this example, the inventors of the present invention mixed ATRA (all-trans retinoic acid) and chicken ovalbumin (OVA) and applied it to the vaginal mucosa of mice to observe the direction of OVA-specific CD8+ T cells towards reproduction. mucosal migration and eventual formation of T RM the process of.

[0038] Reagent

[0039] 1. ATRA, OVA and DMSO were purchased from SigmaAldrich;

[0040] 2. Experimental mice C57BL / 6 were purchased from Shanghai Slack Company, and OT-I mice were bred and bred in our laboratory.

[0041] method

[0042] 1. ATRA dissolution method: ATRA is dissolved in DMSO at a concentration of 30mg / ml, and stored at -80°C in the dark; when used, it is diluted 10 times with soybean oil to 3mg / ml, and applied to mice alone or mixed with 5mg / ml OVA mucous membrane site;

[0043] 2. Mice vaginal mucosa administration method: Use a pipette to absorb 30 μl of soybean oil to dissolve and dilute the ATRA or ATRA / OVA mixture, and gently push it into t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology and particularly relates to a pharmaceutical application of all-trans-retinoic acid.By extensive and deep researches, the new application of the all-trans-retinoic acid to preparation of medicines capable of inducing formation of tissue resident memory T cells is discovered for the first time and lays a foundation for development of brand-new mucosal immunization strategies taking the ATRA (all-trans-retinoic acid) as an adjuvant.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the pharmaceutical use of all-trans retinoic acid. Background technique [0002] All-trans retinoic acid (all-trans-Retinoic acid, ATRA) is also known as retinoic acid, other names such as retinoic acid, retinoic acid, etc., the chemical name is (13E)-3,7-dimethyl-9-(2 , 6,6-trimethylcyclohexenyl)-2,4,6,8-nonatetonic acid, the molecular formula is C 20 h 28 o 2 , is mainly a derivative of vitamin A acid, an intermediate metabolite of vitamin A in the body, and is an indispensable substance for maintaining growth and development. It has a strong ability to induce cell differentiation and immune regulation, and is currently the first choice for clinical treatment of acute promyelocytic leukemia (acutepromyelocyticleukemia, APL), bone marrow dysplasia and other hematological malignancies. There are also good applications in other clinical fields such as related diseases....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/203A61P37/02
CPCA61K31/203
Inventor 李亮助朱建伟
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com